Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 2/20 | 0.33 |
| ▸ | LMNA | P02545 | 2/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3754285 | 0.98 | MEN1 (0.36) | MEN1LMNAKMT2AALDH1A1ALOX12 | |
| SCHEMBL4489949 | 0.95 | — | — | |
| SCHEMBL16053853 | 0.90 | — | — | |
| SCHEMBL28612501 | 0.78 | NCF1 (0.40) | — | |
| SCHEMBL28211801 | 0.77 | CYP2D6 (0.32) | MEN1LMNAKMT2AALDH1A1ALOX12 | |
| SCHEMBL26257483 | 0.77 | CYP1A2 (0.32) | MEN1LMNAKMT2AALDH1A1ALOX12 | |
| SCHEMBL17976970 | 0.75 | CYP1A2 (0.36) | MEN1LMNAKMT2AALDH1A1ALOX12 | |
| SCHEMBL16935658 | 0.75 | SIGMAR1 (0.33) | MEN1LMNAKMT2AALDH1A1ALOX12 | |
| SCHEMBL8850626 | 0.74 | SMN1; SMN2 (0.32) | MEN1LMNAKMT2AALDH1A1ALOX12 | |
| SCHEMBL345668 | 0.74 | SMN1; SMN2 (0.39) | MEN1LMNAKMT2AALDH1A1ALOX12 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090275619-A1 | Amide Substituted Indazole and Benzotriazole Derivatives as Poly(ADP-Ribose)Polymerase (PARP) Inhibitors | ISTITUTO DI RICERCHE DI BIOLOGIA MOLECOLARE P. ANGELETTI SPA (IT) | 2009-11-05 | — | — | US | disclosed |
| US-3965220-A | AMINE CATALYST | MONSANTO COMPANY (US) | 1976-06-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090275619-A1 | Amide Substituted Indazole and Benzotriazole Derivatives as Poly(ADP-Ribose)Polymerase (PARP) Inhibitors | PARP1, PARP3, PARP2 | MEN1 4518/4885LMNA 1363/4885KMT2A 1416/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.